Suzhou Fangde Menda new drug development Co., Ltd. was founded by a team of senior returnees and registered in Wujiang Development Zone in July 2012, with a registered capital of 10 million yuan. In 2019, the company obtained a round of PREA financing of 65 million yuan led by a well-known industrial fund. The company focuses on the development and clinical application of tumor immune cell therapy drugs dominated by allogeneic chimeric antigen receptor T cell (thiscart) platform technology and targeted at first in class. & nbsp; & nbsp; & nbsp; The company has established a GMP workshop for cell therapy, molecular biology and cell biology laboratories in line with international standards, as well as an advanced quality control laboratory, and is carrying out clinical research on allogeneic cart cell drugs for targets such as CD19, CD22 and BCMA.
The company adheres to the guidance of clinical demand, talents as the foundation, technology as the support, capital as the link, the purpose of benefiting human health, the goal of pursuing the development of immunotherapy products and targeted drugs to solve cancer patients, and relying on strong R & D strength, the company will jointly make a contribution to cancer research, new biological drug research and development and immunotherapy drug development in China.
The company focuses on the platform technology of allogeneic chimeric antigen receptor T cells (thiscart)
Talent as the foundation, technology as the support, capital as the link, and the purpose of benefiting human health
Make a contribution to China's cancer research, research and development of new biological drugs and development of immunotherapeutic drugs